Stockscreener 앱 받기
1.89
3.28%
0.06
시간 외 거래:
1.93
0.04
+2.12%
전일 마감가:
$1.83
열려 있는:
$1.83
하루 거래량:
25,472
Relative Volume:
0.24
시가총액:
$3.42M
수익:
$12.99M
순이익/손실:
$-27.83M
주가수익비율:
-0.00928
EPS:
-203.7366
순현금흐름:
$-26.98M
1주 성능:
+2.72%
1개월 성능:
-23.17%
6개월 성능:
-57.29%
1년 성능:
-93.44%
1일 변동 폭
$1.818
$1.90
1주일 범위
$1.8001
$1.90
52주 변동 폭
$1.37
$35.64
Aptevo Therapeutics Inc Stock (APVO) Company Profile
명칭
Aptevo Therapeutics Inc
전화
206-838-0500
주소
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
1.89 | 3.42M | 12.99M | -27.83M | -26.98M | -203.74 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-11-05 | 개시 | Ladenburg Thalmann | Buy |
| 2017-10-05 | 재개 | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc 주식(APVO)의 최신 뉴스
Aptevo advances APVO-451 toward IND-enabling studies - BioWorld News
Aptevo Advances Next-Generation Trispecific Immuno-Oncology Programs - tipranks.com
Aptevo Therapeutics (APVO) Advances Trispecific Therapies Amid C - GuruFocus
Aptevo advances trispecific cancer therapy manufacturing - Investing.com
Aptevo Advances Trispecific APVO451 Toward Clinical Development - ACCESS Newswire
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development - The Batesville Daily Guard
Aptevo Shareholders Approve Equity Issuance, Reject Charter Changes - tipranks.com
Aptevo (APVO) Gains +5.23% — Support Holds at $1.72 2026-09-17Up Down Ratio - dars.gov.et
APVO StockImmuno-Oncology Company To Watch Petersburg (cK2qyfq7CG) - Mshale
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial - Benzinga
Aptevo Therapeutics (NASDAQ: APVO) Registers 6.44M Shares for Holder Resale Following Warrant Exercises - kalkinemedia.com
Aptevo Therapeutics (APVO) Shares Fall Despite Roth Capital Opti - GuruFocus
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo reports 93% clinical benefit rate in AML trial subset By Investing.com - Investing.com Nigeria
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML - Yahoo Finance
Why is Aptevo Therapeutics stock slumping today? By Investing.com - Investing.com Canada
$Aptevo Therapeutics (APVO.US)$ [Strong][Smile][Heart][Rose][Leek] - Moomoo
Aptevo Therapeutics (APVO) Reports Promising AML Trial Results A - GuruFocus
Aptevo Reports Promising Mipletamig Data in TP53-Mutant AML - TipRanks
Aptevo reports 93% clinical benefit rate in AML trial subset - Investing.com
Aptevo Reports Strong Mipletamig Results in TP53-Mutated AML - ACCESS Newswire
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML - FinancialContent
Aptevo Therapeutics Inc. SEC Filing (Sep 3, 2026) - Stock Titan
Aptevo Therapeutics Inc. (APVO) Peer Comparison – Compare with Others - Value Research
12 Health Care Stocks Moving In Wednesday's After-Market SessionGelteq (NASDAQ:GELS), Nyxoah (NASDAQ:N - Benzinga
Aptevo Therapeutics Inc. (APVO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Times Herald-Record
Aptevo Therapeutics (APVO) quietly closes private funding round - Stock Titan
Aptevo (APVO) Momentum: Moves 10.07% Down to $2.41 for the Current Session; Next Test: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingHagopian Line - vinanet.vn
Aptevo Shareholders Back Board, Auditor and Incentive Plan - TipRanks
Aptevo (NASDAQ: APVO) asks holders to approve dilutive warrant deal - Stock Titan
Weekly Recap: APVO H1 losses and Aug 13 financing via warrants, PIPE - TradingView
Aptevo Therapeutics (APVO): CVI and Heights disclose 6.3% warrant-based stake - Stock Titan
Aptevo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aptevo Therapeutics Inc.: Financial Data Forecasts Estimates and Expectations | AP8 | US03835L3069 - marketscreener.com
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Aptevo Therapeutics Inc. 6M 2026: Net loss $(13.15M), Diluted EPS $(11.19) — 10-Q Summary - TradingView
Aptevo APVO Reports Q2 2026 Update With $9.8 Million Cash - Quiver Quantitative
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - ACCESS Newswire
Aptevo Q2 Results: Cash at $9.8m, Mipletamig Advances - scanx.trade
Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing - TipRanks
Aptevo raises $4.5 million through warrant and equity financing By Investing.com - Investing.com Nigeria
Aptevo Raises $4.5 Million Via Warrant Exercises and PIPE; Issues 5.6M Warrants at $4.03 - TradingView
Aptevo raises $4.5 million through warrant and equity financing - Investing.com
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds - ACCESS Newswire
New Aptevo warrants for 4.3M shares await stockholder approval - Stock Titan
Aptevo Therapeutics Inc. (APVO) Stock: New Financing Targets $4.5M in Gross Proceeds - Blockonomi
Aptevo raises $4.5M through warrant exercises and private placement By Investing.com - Investing.com South Africa
Aptevo raises $4.5M through warrant exercises and private placement - Investing.com
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds - ACCESS Newswire
News by ACCESS Newswire on TradingView, 2026-08-12 - TradingView
Aptevo Therapeutics Inc (APVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):